ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET.
| To participate, please use the following numbers: | |
| France: | +33 (0)1 70 730 3 39 |
| Germany: | +49 (0)69 22222 5197 |
| Italy: | +39 0200638217 |
| Switzerland: | +41 (0)44 580 7279 |
| United Kingdom: | +44 (0)330 165 4012 |
| United States: | +1 646-828-8073 |
Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis H1 2022 Financial Results and Business Update” – and the following confirmation code: 7688870.
The presentation will also be available via webcast:
- For participants of the conference call: https://www.webcast-eqs.com/spexis20220906/ no-audio (audio via phone, presentation on the web browser)
- Live stream: https://www.webcast-eqs.com/spexis20220906 (audio and presentation on the web browser; for passive participants)
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.
In addition, management will participate at the following events in September:
- German Fall Conference (Herbstkonferenz)
September 5-6, 2022, Frankfurt, Germany
Stephan Wehselau, COO, will give a company presentation on September 6th at 10:45 AM CET and will also meet with investors.
- Sachs Associates 22nd Annual Biotech in Europe Forum
September 21-22, 2022, Basel, Switzerland
Dr. Wager will give a company presentation and meet with investors.
- BioPharm America
September 28-29, 2022, Boston, U.S. (in-person) & October 4-5, 2022 (virtual)
Dr. Wager will participate in this partnering event. Anyone interested in speaking with the company is invited to request a meeting via the PARTNERINGONE® platform.
For further information please contact:
| For Investors: Hernan Levett Chief Financial Officer Spexis AG. +41 61 567 16 00 IR@spexisbio.com Raimund Gabriel MC Services spexis@mc-services.eu Ph: +49 89 210 228 0 | For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 feldhaus@feldhaus-partner.ch Dr. Brigitte Keller/Laurie Doyle MC Services spexis@mc-services.eu Europe: +49 89 210 228 0 U.S.: +1 339 832 0752 |
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com.
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
